The 13-year results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) have recently been published.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Authors presented a 'substantial' reduction in prostate cancer-specific mortality of 20%. However, absolute risk reduction is very small (0.11 per 1000 person years) and no effect was shown on all-cause mortality. Additionally, the number of unnecessary prostate cancer diagnoses and the number of diagnostic procedures for this small effect are considerable. We believe that the discussion on the introduction of a population-based screening programme for prostate cancer could be at an end. Prostate cancer detection should be limited to men with signs or symptoms of the disease. Prostate-specific antigen (PSA) testing in non-symptomatic men should be a patient's personal decision, after weighing the pros and cons of any subsequent procedures.
Blanker MH, Noordzij MA. Are you the author?
Rijksuniversiteit Groningen, Universitair Medisch Centrum Groningen, afd. Huisartsgeneeskunde, Groningen.
Reference: Ned Tijdschr Geneeskd. 2014;158:A8349.
Article in Dutch.